Activation of α4* nAChRs is Necessary and Sufficient for Varenicline-Induced Reduction of Alcohol Consumption
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Recently, the smoking cessation therapeutic varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, has been shown to reduce alcohol consumption. However, the mechanism and nAChR subtype(s) involved are unknown. Here we demonstrate that varenicline and alcohol exposure, either alone or in combination, selectively activates dopaminergic (DAergic) neurons within the posterior, but not the anterior, ventral tegmental area (VTA). To gain insight into which nAChR subtypes may be involved in the response to alcohol, we analyzed nAChR subunit gene expression in posterior VTA DAergic neurons. Ethanol-activated DAergic neurons expressed higher levels of α4, α6, and β3 subunit genes compared with nonactivated neurons. To examine the role of nicotinic receptors containing the α4 subunit (α4* nAChRs) in varenicline-induced reduction of alcohol consumption, we examined the effect of the drug in two complementary mouse models, a knock-out line that does not express the α4 subunit (α4 KO) and another line that expresses α4* nAChRs hypersensitive to agonist (Leu9′Ala). While varenicline (0.1–0.3 mg/kg, i.p.) reduced 2% and 20% alcohol consumption in wild-type (WT) mice, the drug did not significantly reduce consumption in α4 KO animals. Conversely, low doses of varenicline (0.0125–0.05 mg/kg, i.p.) that had little effect in WT mice dramatically reduced ethanol intake in Leu9′Ala mice. Infusion of varenicline into the posterior, but not the anterior VTA was sufficient to reduce alcohol consumption. Together, our data indicate that activation of α4* nAChRs is necessary and sufficient for varenicline reduction of alcohol consumption.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mammalian nicotinic acetylcholine receptors: from structure to function
Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., & Rogers, S. W. (2009) · Physiological Reviews · doi:10.1152/physrev.00015.2008 · Cited by 1,724
Jorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635 · cited 2×
“While varenicline was designed as a selective 4 2* nAChR partial agonist (Coe et al., 2005; Jorenby et al., 2006), it is also a partial agonist at 3 2* and 6* nAChR subtypes, and a full agonist at 3 4* and 7 nAChR subtypes (Mihalak et al., 2006).”
BackgroundMethodIkemoto, S. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.05.004 · Cited by 1,477
Gonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 1×
“The nAChR partial agonist, varenicline, is an FDA approved smoking cessation aid that may hold promise as a treatment for alcoholism (Coe et al., 2005; Gonzales et al., 2006).”
BackgroundVarenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930 · cited 3×
“While varenicline was designed as a selective 4 2* nAChR partial agonist (Coe et al., 2005; Jorenby et al., 2006), it is also a partial agonist at 3 2* and 6* nAChR subtypes, and a full agonist at 3 4* and 7 nAChR subtypes (Mihalak et al., 2006).”
BackgroundMethodNicotine activates and desensitizes midbrain dopamine neurons
Pidoplichko, V. I., DeBiasi, M., Williams, J. T., & Dani, J. A. (1997) · Nature · doi:10.1038/37120 · Cited by 769
Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas
Mansvelder, H. D., Keath, J. R., & McGehee, D. S. (2002) · Neuron · doi:10.1016/s0896-6273(02)00625-6 · Cited by 701 · cited 1×
“Alcohol activates DAergic neurons within this region, ultimately increasing DA release in the NAc and driving dependence (Pidoplichko et al., 1997; Brodie and Appel, 1998; Brodie et al., 1999; Mansvelder et al., 2002).”
BackgroundNicotine Activation of α4* Receptors: Sufficient for Reward, Tolerance, and Sensitization
Tapper, A. R., McKinney, S. L., Nashmi, R., Schwarz, J., Deshpande, P., Labarca, C., Whiteaker, P., Marks, M. J., Collins, A. C., & Lester, H. A. (2004) · Science · doi:10.1126/science.1099420 · Cited by 686
Self-citationVarenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558
Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533 · cited 1×
“This would also be consistent with the mechanism by which varenicline is thought to reduce nicotine reinforcement (Rollema et al., 2007).”
Result
Cited by
Nicotinic acetylcholine receptors: From basic science to therapeutics
Hurst, R., Rollema, H., & Bertrand, D. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.012 · Cited by 522
Zhao-Shea, R., Liu, L., Pang, X., Gardner, P. D., & Tapper, A. R. (2013) · Current Biology · doi:10.1016/j.cub.2013.09.041 · Cited by 129
Self-citationDivergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal
Turner, J. R., Wilkinson, D. S., Poole, R. L., Gould, T. J., Carlson, G. C., & Blendy, J. A. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.105 · Cited by 29
Moen, J. K., & Lee, A. M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.745783 · Cited by 30
Aranäs, C., Blid Sköldheden, S., & Jerlhag, E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1180512 · Cited by 20
“While previous studies in male rats report that varenicline decreases alcohol drinking (Steensland et al., 2007; Ericson et al., 2009; Hendrickson et al., 2010; Feduccia et al., 2014; Froehlich et al., 2017), this was not confirmed in the present study of male and female rats using a similar dose of varenicline.”
BackgroundResult
Metadata
- Authors
- Hendrickson, L. M., Zhao-Shea, R., Pang, X., Gardner, P. D., & Tapper, A. R.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2010-07-28
- Volume
- 30
- Issue
- 30
- Pages
- 10169-10176
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2033170773
- Cited by
- 99
- References
- 15
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activation of α4* nAChRs is Necessary and Sufficient for Varenicline-Induced Reduction of Alcohol Consumption. https://app.cochat.ai/papers/10.1523/jneurosci.2601-10.2010
- The paper
- Hendrickson, L. M., Zhao-Shea, R., Pang, X., Gardner, P. D., & Tapper, A. R. (2010). Activation of α4* nAChRs is Necessary and Sufficient for Varenicline-Induced Reduction of Alcohol Consumption. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.2601-10.2010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.